Clinical Reference Guide
Technical specifications, regulatory status, mechanism of action and safety documentation for the Lumnae ONE / PLUS / PRO red light therapy panels — prepared for healthcare professionals.
Scope of this device: Lumnae panels are registered with the FDA as Class II, 510(k) exempt devices under product code ILY — "Lamp, infrared, therapeutic heating" (21 CFR 890.5500). They are general-wellness photobiomodulation devices. They are not cleared or marketed to diagnose, treat, cure, mitigate or prevent any specific disease, including but not limited to depression or other psychiatric conditions, diabetic neuropathy or other neuropathies, thyroid disorders, osteoporosis, or any other diagnosed medical condition. Content below describes the device's technical characteristics and the general photobiomodulation research literature; it does not constitute a claim of clinical efficacy for any named condition.
What Lumnae Panels Are
Lumnae ONE, PLUS and PRO are LED-based photobiomodulation (PBM) panels delivering nine discrete wavelengths across the visible-red and near-infrared spectrum (480–1060nm). All three models share identical spectral output, irradiance, and control architecture; they differ in physical size and total LED count, positioning them for targeted, half-body, and full-body use respectively.
Devices are manufactured by Shenzhen Idea Light Limited (FDA Owner/Operator 10060135) and distributed by Lumnae (ELM Company FZ-LLC, Dubai, UAE) under private label.
Technical Specifications
| ONE | PLUS | PRO | |
|---|---|---|---|
| Panel size | 32×23×6.5cm | 92×30×6.5cm | 184×42×6.5cm |
| LEDs | 72 (144 dual-chip) | 288 (576 dual-chip) | 864 (1,728 dual-chip) |
| Weight | 4.2kg ±0.5kg | 13.5kg ±0.5kg | 30kg ±0.5kg |
| Rated power | 120W | 480W | 1,440W ±10% |
| Irradiance @ 15cm | 160 mW/cm² (all models) | ||
| Working current | 0.918A/220V · 1.549A/110V | 4.0A/220V · 6.6A/110V | 12A/220V · 16A/110V |
| Input voltage | AC100–240V | ||
| Beam angle | 30° (customised lens) | ||
| EMF emission | 0.0 µT @ 15cm | ||
| UV emission | Zero | ||
| Flicker | Zero (medical-grade drivers) | ||
| LED rated lifespan | 50,000 hours | ||
| Control resolution | 0–100% intensity, 0–10,000Hz pulse, independently per wavelength | ||
| Operating temp | 5–50°C | ||
| Warranty | 3 years, manufacturing defects & component failure under normal use | ||
Mechanism of Action
Photobiomodulation (PBM) delivers specific wavelengths of red and near-infrared light to tissue, where photons are absorbed by the mitochondrial enzyme cytochrome c oxidase (Complex IV) of the electron transport chain. This absorption is the accepted primary mechanism underlying PBM's downstream cellular effects, which are reported in the literature to include:
- Increased ATP production via enhanced mitochondrial respiration
- Transient increase in reactive oxygen species triggering redox-sensitive transcription factors
- Nitric oxide release from cytochrome c oxidase, contributing to localised vasodilation
- Modulation of inflammatory mediators
Visible red light (480–670nm) is absorbed predominantly at the skin surface and upper dermis. Near-infrared light (810–1060nm) is minimally absorbed by melanin, haemoglobin and water, creating an "optical window" that allows deeper tissue penetration (reported in the literature in the range of 3–5cm depending on wavelength and tissue type).
The 9 Wavelengths
| λ | Band | Approx. penetration | Primary literature focus |
|---|---|---|---|
| 480nm | Blue | 1–2mm (epidermis) | Surface porphyrin activation |
| 590nm | Amber | Superficial dermis | Lymphatic/microcirculatory modulation |
| 630nm | Red | Upper dermis | Superficial fibroblast/collagen activity |
| 660nm | Red | Dermis | Peak CCO absorption; most-studied PBM wavelength |
| 670nm | Red | Dermis | Overlaps 660nm absorption band |
| 810nm | NIR | Deep tissue; transcranial window | Muscle/joint tissue; active transcranial PBM research area |
| 830nm | NIR | Deep tissue | Connective tissue, deep muscle |
| 850nm | NIR | Deep tissue | Most-referenced NIR wavelength for muscle recovery literature |
| 1060nm | Far NIR | Deepest (~4–5cm reported) | Structural/deep tissue depth; distinct absorption profile from other NIR |
Note: 1060nm clinical fat-reduction literature (e.g. Kislevitz et al., Aesthetic Surgery Journal, 2021) concerns dedicated high-power thermal diode laser devices administered in clinical settings — a different device category, power density and mechanism (controlled hyperthermia) than Lumnae's low-level LED panels. This is not evidence of equivalent effect from LED-based photobiomodulation.
Dosimetry & Session Parameters
Distance guidance: skin surface 10–15cm · deep tissue 15–25cm · scalp 10–20cm. Fluence (J/cm²) is a function of irradiance × time; device touchscreen displays timer only, not calculated fluence — clinicians using the device for reference should calculate J/cm² manually from irradiance and session duration for comparison against published dose-response literature.
Regulatory Status
| FDA status | Registered — Class II device (USA), 510(k) exempt |
| FDA product code | ILY — Lamp, infrared, therapeutic heating (21 CFR 890.5500) |
| FDA registration number | 3015287734 |
| CE | Certified — European Conformity |
| ISO 13485 | Medical devices quality management |
| IEC 60601-1 | Medical electrical equipment standard |
| RoHS | Compliant |
510(k) exempt status means the device is not required to undergo FDA premarket review for the general wellness/infrared-heating indication under its product code. It does not imply clearance for any specific therapeutic indication.
Safety & Contraindications
Per the Lumnae User Manual, patients should consult their physician before use if any of the following apply:
| Pregnancy / breastfeeding | Do not use without medical clearance |
| Active cancer / suspected malignancy | Do not use without explicit oncologist clearance |
| Photosensitivity / photosensitising medication | Includes certain conditions (e.g. lupus) and medications (antibiotics, diuretics) |
| Epilepsy / light-triggered seizures | Pulse mode creates a strobe effect — avoid pulse; goggles mandatory |
| Open wounds, active lesions, recent sunburn | Avoid treating directly; wait 2 weeks post-sunburn |
| Hyperthyroidism | Avoid prolonged exposure to neck and upper chest |
| Fever / active systemic infection | Avoid sessions; consult physician before resuming |
| Eye conditions | Goggles mandatory at all times; consult ophthalmologist before facial sessions |
| Implants / medical devices | Generally considered safe; verify with treating physician |
| Fitzpatrick V–VI | May experience marginally more surface warmth; start at lower intensity |
Devices carry zero UV emission and zero flicker (medical-grade drivers). EMF emission is 0.0 µT at 15cm. Manufacturer states no known serious adverse effects at therapeutic doses; goggles are mandatory during all sessions regardless of protocol.
Evidence Summary by Application Area
The following reflects the general photobiomodulation research literature at the wavelength/mechanism level. It does not represent clinical trials conducted by Lumnae on Lumnae devices, and is not a claim that Lumnae panels treat any listed condition.
| Area | Primary wavelengths | Evidence character |
|---|---|---|
| Collagen / skin quality | 630, 660nm | Best-established PBM application; substantial peer-reviewed literature including controlled trials |
| Muscle recovery / DOMS | 850, 830nm | Multiple sports-medicine RCTs; among the more consistently replicated PBM outcomes |
| Mood / transcranial PBM | 810nm | Active, growing research area; meta-analyses (e.g. Ji et al. 2024, 11 RCTs) report positive signal; mechanism and optimal dosing still being established |
| Deep tissue / joint comfort | 830, 850, 1060nm | Emerging; more limited controlled-trial base than skin/muscle applications |
| Hair / scalp | 630–670, 810nm | Emerging; low-level light therapy for hair has some regulatory precedent in dedicated devices, not directly extrapolated from this device class |
Further Information
For B2B enquiries, device loans for evaluation, or specific technical questions not covered here, contact contact@lumnae.com.
This page is provided for informational purposes to healthcare professionals evaluating the device. It does not constitute medical advice, a clinical claim, or promotional material implying treatment efficacy for any specific condition. Lumnae panels do not diagnose, treat, cure, mitigate or prevent any disease.